Evidence map›Paper›PMID 40722347›Full record

ArticleBrain sciences2025

Delving into the Perception, Use, and Context of Duloxetine in Clinical Practice: An Analysis Based on the Experience of Healthcare Professionals.

Oscar Fraile-Martinez, Cielo Garcia-Montero, Miguel Angel Alvarez-Mon, Miguel A Ortega, Melchor Alvarez-Mon, Javier Quintero

Abstract read
In one paragraph

Article in Brain sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Oscar Fraile-MartinezDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Madrid, Spain.ORCID 0000-0002-4494-6397
Cielo Garcia-MonteroDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Madrid, Spain.ORCID 0000-0001-6016-7855
Miguel Angel Alvarez-MonDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Madrid, Spain.
Miguel A OrtegaDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Madrid, Spain.ORCID 0000-0003-2588-1708
Melchor Alvarez-MonDepartment of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Madrid, Spain.ORCID 0000-0003-1309-7510
Javier QuinteroDepartment of Psychiatry and Mental Health, University Hospital Infanta Leonor, 28031 Madrid, Spain.ORCID 0000-0002-2491-8647

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesDuloxetine is widely used for the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), and various types of neuropathic pain. While its efficacy is well documented in clinical trials, less is known about how it is perceived and utilized in routine psychiatric practice. To address this knowledge gap, we conducted a cross-sectional observational study involving 80 psychiatrists from Spain to assess real-world clinical attitudes toward duloxetine.

methodsParticipants completed a 20-item multiple-choice questionnaire that examined familiarity, perceived efficacy in multiple conditions (MDD, GAD, neuropathic pain, somatization, and quality of life), and perspectives on tolerability, safety, adherence, and overall satisfaction.

resultsSurvey results indicated that a large majority of psychiatrists frequently prescribe duloxetine, particularly for patients with MDD and comorbid chronic pain. Notably, 94% rated it as either "more effective" or "much more effective" for diabetic peripheral neuropathic pain. Psychiatrists reported a high perceived efficacy of duloxetine: 94% rated it as "more effective" or "much more effective" for diabetic peripheral neuropathy, and 93% gave similarly positive ratings for general neuropathic pain. For somatization, 70% found it "effective" or "very effective", and 83% observed improvements in quality of life for many of their patients. Psychiatrists generally reported favorable perceptions of duloxetine's tolerability profile: 97.5% rated it as the antidepressant associated with the least weight gain, and 82.5% perceived fewer sexual side effects compared to other options. Sedation and gastrointestinal side effects were generally considered mild or less severe. In terms of treatment adherence, 69% rated it as "better" or "much better" than other antidepressants, and 80% found its combination with other antidepressants to be "favorable" or "very favorable". Overall satisfaction was high, with 99% of psychiatrists reporting being either "satisfied" or "very satisfied" with its use. The side effect profile was generally viewed as manageable, with low perceived rates of weight gain, sedation, and sexual dysfunction. Furthermore, 96% of respondents expressed a willingness to recommend duloxetine to their colleagues.

conclusionsPsychiatrists reported highly favorable attitudes toward duloxetine, viewing it as a flexible treatment option in routine care. However, these findings reflect clinicians' subjective perceptions rather than objective clinical outcomes and should be interpreted accordingly.

Indexed as

adherencechronic painduloxetineefficacygeneralized anxiety disorder (GAD)major depressive disorder (MDD)perceived satisfactiontolerability

Identifiers

PMID40722347
PMCPMC12293169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.